GlassScriptPhysician profile
Jeffrey Ma
NPI 1265819155
$5,140.58
in general payments reported to CMS, 2019-2025
26 companies · $1,086 in 2025
The $1,086 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $34.02 · 2021: $377 · 2022: $607 · 2023: $1,247 · 2024: $1,790 · 2025: $1,086.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,122.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $910.30 | 2021-2025 | Verquvo, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $792.35 | 2021-2025 | Jardiance, Synjardy |
| Novo Nordisk INC | $730.53 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Actelion Pharmaceuticals US, INC. | $419.82 | 2023-2025 | Opsumit |
| Esperion Therapeutics, INC. | $418.53 | 2021-2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $349.30 | 2023-2024 | Xarelto |
| Lilly USA, LLC | $221.58 | 2022-2024 | Mounjaro |
| Abbott Laboratories | $204.12 | 2023-2025 | Jot Dx, Aveir, Proclaim |
| Heartflow, INC. | $138.86 | 2024-2025 | |
| Abbvie INC. | $122.19 | 2024 | |
| Sanofi-Aventis U.S. LLC | $106.00 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $90.01 | 2024-2025 | |
| Lexicon Pharmaceuticals, INC. | $76.39 | 2023-2024 | Inpefa |
| Exact Sciences Corporation | $73.74 | 2023-2024 | Cologuard Collection Kit |
| Boston Scientific Corporation | $73.49 | 2024-2025 | Watchman Flx, Latitude Communicator Power Supply |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $59.57 | 2023-2024 | Repatha, Krystexxa |
| Agepha Pharma Fz LLC | $53.12 | 2025 | Lodoco |
| Pfizer INC. | $50.08 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $48.95 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $39.46 | 2023-2024 | Farxiga, Airsupra |
| Alcon Vision LLC | $34.02 | 2020 | |
| Scpharmaceuticals INC. | $31.24 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $27.53 | 2024 | Evkeeza |
| Phathom Pharmaceuticals, INC. | $27.37 | 2024 | Voquezna |
| Csl Behring | $21.12 | 2023 | Hizentra |
| Medtronic, INC. | $20.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Ma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.